Abstract
Numerous studies have confirmed that angiogenesis acts as a momentous process in pancreatic cancer (PC) developmental stages in tumor growth, proliferation, differentiation, and metastasis. Proangiogenic factor overexpression such as fibroblast growth factor (FGF), tumor necrosis factor (TNF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) initiates progression of angiogenesis in the tumor cells. Among these VEGF and PDGFR have been confirmed as strong angiogenic factors. Overexpression of these factors has an imperative function in each step of angiogenesis development during tumor progression, recurrence, and fewer prognoses in pancreatic carcinomas. This chapter covers elementary biology of VEGF and PDGFR and their expression as prognostic biomarkers in pancreatic cancer. Overexpression of VEGF–PDGFR-mediated signaling pathways associated with pancreatic cancer metastasis and accumulating diverse therapeutic targets of VEGF and PDGFR complex are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30
Herreros-Villanueva M, Bujanda L (2016) Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Ann Transl Med 4:134
Malhotra L, Ahn D, Bloomston M (2015) The pathogenesis, diagnosis, and management of pancreatic cancer. J Gastrointest Dig Syst 4:295
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114
Klöppel G, Basturk O, Schlitter AM, Konukiewitz B, Esposito I (2014) Intraductal neoplasms of the pancreas. Semin Diagn Pathol, Elsevier:452–466
Riess HB, Goerke A, Oettle H (2008) Pancreatic cancer. Springer, Berlin
Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD (2004) Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 239:788
Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP (2002) Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Sci 9:1–11
Garcea G, Neal C, Pattenden C, Steward W, Berry D (2005) Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 41:2213–2236
Shi Q, Le X, Wang B, Abbruzzese JL, **ong Q, He Y, **e K (2001) Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20:3751
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580
Karar J, Maity A (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4:51
Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32
Verheul H, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187–2190
Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C (1994) Macrophages and angiogenesis. J Leukoc Biol 55:410–422
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22
Niu G, Chen X (2010) Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11:1000–1017
Holmes DI, Zachary I (2005) The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 6:209
Brissova M, Aamodt K, Brahmachary P, Prasad N, Hong J-Y, Dai C, Mellati M, Shostak A, Poffenberger G, Aramandla R (2014) Islet microenvironment, modulated by vascular endothelial growth factor-A signaling, promotes β cell regeneration. Cell Metab 19:498–511
Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549–560
Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes Cancer 2:1097–1105
Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, Frank N, Bogaert E, Claes B, Heylen L, Verheyen A (2008) Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J Neurosci 28:10451–10459
Salven P, Lymboussaki A, Heikkilä P, Jääskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H (1998) Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103–108
Muoio DM (2010) Metabolism and vascular fatty acid transport. N Engl J Med 363:291–293
Zafar MI, Zheng J, Kong W, Ye X, Gou L, Regmi A, Chen L-L (2017) The role of vascular endothelial growth factor-B in metabolic homoeostasis: current evidence. Biosci Rep 37:BSR20171089
Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L (2009) VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci 106:6152–6157
Paavonen K, Horelli-Kuitunen N, Chilov D, Kukk E, Pennanen S, Kallioniemi O-P, Pajusola K, Olofsson B, Eriksson U, Joukov V (1996) Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation 93:1079–1082
Jha SK, Rauniyar K, Karpanen T, Leppänen V-M, Brouillard P, Vikkula M, Alitalo K, Jeltsch M (2017) Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. Sci Rep 7:4916
Marconcini L, Marchiò S, Morbidelli L, Cartocci E, Albini A, Ziche M, Bussolino F, Oliviero S (1999) c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci 96:9671–9676
El-Chemaly S, Pacheco-Rodriguez G, Malide D, Meza-Carmen V, Kato J, Cui Y, Padilla PI, Samidurai A, Gochuico BR, Moss J (2014) Nuclear localization of vascular endothelial growth factor-D and regulation of c-Myc–dependent transcripts in human lung fibroblasts. Am J Respir Cell Mol Biol 51:34–42
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci 95:548–553
Lyttle DJ, Fraser KM, Fleming SB, Mercer AA, Robinson AJ (1994) Homologs of vascular endothelial growth factor are encoded by the poxvirus Orf virus. J Virol 68:84–92
Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C (1999) A novel vascular endothelial growth factor encoded by Orf Virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18(2):363–374
Wise LM, Inder MK, Real NC, Stuart GS, Fleming SB, Mercer AA (2012) The vascular endothelial growth factor (VEGF)-E encoded by Orf virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration. Cell Microbiol 14:1376–1390
Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273–31282
Jenkinson DM, McEwan PE, Moss VA, Elder HY (1990) Location and spread of Orf virus antigen in infected ovine skin. Vet Dermatol 1:189–195
Yamazaki Y, Matsunaga Y, Tokunaga Y, Obayashi S, Saito M, Morita T (2009) Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J Biol Chem 284:9885–9891
Takahashi H, Hattori S, Iwamatsu A, Takizawa H, Shibuya M (2004) A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J Biol Chem 279:46304–46314
Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del SV, Lei K, Chou JY, Persico M (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8:925–931
Loges S, Schmidt T, Carmeliet P (2009) “Antimyeloangiogenic” therapy for cancer by inhibiting PlGF. Clin Cancer Res 15:3648–3653
Korc M (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2:8
Stuttfeld E, Ballmer-Hofer K (2009) Structure and function of VEGF receptors. IUBMB Life 61:915–922
Sipos B, Klapper W, Kruse M-L, Kalthoff H, Kerjaschki D, Klöppel G (2004) Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol 165:1187–1197
Hansel DE, Rahman A, Hermans J, De Krijger RR, Ashfaq R, Yeo CJ, Cameron JL, Maitra A (2003) Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 16:652
Büchler P, Reber HA, Büchler MW, Friess H, Hines OJ (2002) VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 236:738
Costache M, Ioana M, Iordache S, Ene D, Costache CA, Săftoiu A (2015) VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Rom J Intern Med 53:199–208
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, **ong HQ, Abbruzzese JL (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319–329
Thomas RM, Jaquish DV, French RP, Lowy AM (2010) The RON tyrosine kinase receptor regulates VEGF production in pancreatic cancer cells. Pancreas 39:301
Raica M, Cimpean AM (2010) Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 3:572–599
Heldin C-H, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316
Shim AH-R, Liu H, Focia PJ, Chen X, Lin PC, He X (2010) Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci 107:11307–11312
Bafico A, Aaronson S (2003) Classification of growth factors and their receptors, Holland-Frei Cancer Medicine, 6th edn. BC Decker, Hamilton
Heldin C-H, Lennartsson J (2013) Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol 5:a009100
Spritz R, Strunk K, Lee S-T, Lu-Kuo J, Ward D, Le Paslier D, Altherr M, Dorman T, Moir D (1994) A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 22:431–436
Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, Moon S-H, Pfister NT, Tschaharganeh DF, Kitzing T (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 157:382–394
Wang Y, Qiu H, Hu W, Li S, Yu J (2014) Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer. Int J Mol Sci 15:4780–4794
Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, Sarkar FH (2007) Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-κB signaling. Cancer Res 67:11377–11385
Chen H-M, Tsai C-H, Hung W-C (2015) Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget 6:14940
Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL, Fidler IJ (2005) Simultaneous inhibition of EGFR, VEGFR and PDGFR signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65:10371
El-Rayes B, Zalupski M, Shields A, Vaishampayan U, Heilbrun L, Jain V, Adsay V, Day J, Philip P (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920–2925
Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040
Kindler H, Friberg G, Stadler W, Singh D, Locker G, Nattam S, Kozloff M, Kasza K, Vokes E (2004) Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial. J Clin Oncol 22:4009–4009
Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J III, Gibbs J, Iyer R (2009) Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 100:1842
Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB (2012) Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 7:e50165
Bimonte S, Barbieri A, Leongito M, Piccirillo M, Giudice A, Pivonello C, De Angelis C, Granata V, Palaia R, Izzo F (2016) Curcumin anticancer studies in pancreatic cancer. Nutrients 8:433
Shankar S, Nall D, Tang S-N, Meeker D, Passarini J, Sharma J, Srivastava RK (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6:e16530
Widakowich C, de Castro G, De Azambuja E, Dinh P, Awada A (2007) Side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Srivani, G., Bethi, S.R., Aliya, S., Alam, A., Nagaraju, G.P. (2018). VEGFR and PDGFR Targeting in Pancreatic Cancer. In: Nagaraju, G. (eds) Role of Tyrosine Kinases in Gastrointestinal Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-13-1486-5_7
Download citation
DOI: https://doi.org/10.1007/978-981-13-1486-5_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-1485-8
Online ISBN: 978-981-13-1486-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)